AF
KALV

Amalgamated Financial’s KalVista Pharmaceuticals KALV Stock Holding History

Amalgamated Financial’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$54K Buy
+3,652
New +$52.5K ﹤0.01% 2394

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amalgamated Financial's KALV Position: Q1 2022 in Review

Amalgamated Financial opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2022: 3,652 shares worth $54K. The stake represents ﹤0.01% of the portfolio and ranks #2394 among its holdings.

89 funds tracked by Wall St. Rank hold KALV as of Q1 2022.

  • Amalgamated Financial held 3,652 shares of KalVista Pharmaceuticals worth $54K as of Q1 2022.
  • KalVista Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • KalVista Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2394 holding.
  • 89 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.